
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1341800/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the Management of Adults with Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1730-1754.	2.5	2,041
2	SMART OP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 375-384.	2.9	458
3	Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis. Annals of Internal Medicine, 1996, 125, 979.	2.0	445
4	Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Diseases, 2017, 65, 1806-1812.	2.9	366
5	Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infectious Diseases, The, 2011, 11, 181-189.	4.6	210
6	A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1086-1093.	2.5	209
7	Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1756-1762.	1.4	208
8	Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge. Archives of Internal Medicine, 1999, 159, 2449.	4.3	204
9	Acute Myocardial Infarction in Hospitalized Patients with Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, 182-187.	2.9	166
10	Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. International Journal of Infectious Diseases, 2013, 17, e76-e83.	1.5	163
11	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. JAMA - Journal of the American Medical Association, 2021, 326, 46.	3.8	162
12	Incidence of Nephrotoxicity and Association With Vancomycin Use in Intensive Care Unit Patients With Pneumonia: Retrospective Analysis of the IMPACT-HAP Database. Clinical Therapeutics, 2012, 34, 149-157.	1.1	139
13	Thrombocytopenia and Thrombocytosis at Time of Hospitalization Predict Mortality in Patients With Community-Acquired Pneumonia. Chest, 2010, 137, 416-420.	0.4	129
14	Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. European Respiratory Review, 2016, 25, 178-188.	3.0	121
15	Early Switch From Intravenous to Oral Cephalosporins in the Treatment of Hospitalized Patients With Community-Acquired Pneumonia. Archives of Internal Medicine, 1995, 155, 1273.	4.3	114
16	Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2008, 134, 955-962.	0.4	112
17	Infection of Human Endothelial Cells with <i>Chlamydia pneumoniae</i> Stimulates Transendothelial Migration of Neutrophils and Monocytes. Infection and Immunity, 1999, 67, 1323-1330.	1.0	111
18	Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagnostic Microbiology and Infectious Disease, 1996, 24, 7-14.	0.8	108

#	Article	IF	CITATIONS
19	Early Switch From Intravenous to Oral Antibiotics in Hospitalized Patients With Bacteremic Community-Acquired Streptococcus pneumoniae Pneumonia. Archives of Internal Medicine, 2001, 161, 848.	4.3	107
20	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. Archives of Internal Medicine, 2009, 169, 1515.	4.3	106
21	How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Medical Research Methodology, 2011, 11, 144.	1.4	106
22	Hospitalization for Community-Acquired Pneumonia. Chest, 2003, 124, 121-124.	0.4	102
23	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clinical Infectious Diseases, 2018, 67, 1498-1506.	2.9	98
24	Relationship of Vancomycin Minimum Inhibitory Concentration to Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Hospital-Acquired, Ventilator-Associated, or Health-care-Associated Pneumonia. Chest, 2010, 138, 1356-1362.	0.4	95
25	Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest, 2004, 125, 1888-1901.	0.4	92
26	Community-Acquired Pneumonia in the Elderly: Association of Mortality With Lack of Fever and Leukocytosis. Southern Medical Journal, 1997, 90, 296-298.	0.3	91
27	Decrease in Long-term Survival for Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2010, 138, 279-283.	0.4	90
28	Killing of Legionella pneumophila by nitric oxide in Î <sup>3</sup> -interferon-activated macrophages. Journal of Leukocyte Biology, 1992, 52, 625-629.	1.5	85
29	Characterization of a Strain of Chlamydia pneumoniae Isolated from a Coronary Atheroma by Analysis of the omp1 Gene and Biological Activity in Human Endothelial Cells. Infection and Immunity, 1998, 66, 1370-1376.	1.0	83
30	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	3.0	82
31	The Presence of Pneumococcal Bacteremia Does Not Influence Clinical Outcomes in Patients With Community-Acquired Pneumonia. Chest, 2008, 133, 618-624.	0.4	80
32	Proteomic Analysis of Differentially Expressed Chlamydia pneumoniae Genes during Persistent Infection of HEp-2 Cells. Infection and Immunity, 2002, 70, 2976-2981.	1.0	78
33	Characterization of Chlamydia pneumoniae Persistence in HEp-2 Cells Treated with Gamma Interferon. Infection and Immunity, 2001, 69, 7927-7932.	1.0	72
34	A practical iterative procedure to estimate seismic-induced deformations of shallow rectangular structures. Canadian Geotechnical Journal, 2008, 45, 923-938.	1.4	72
35	Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2000, 44, 1796-1802.	1.4	69
36	The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. Annals of the American Thoracic Society, 2016, 13, 1519-1526.	1.5	69

#	Article	IF	CITATIONS
37	Requirement for NF-κB in Transcriptional Activation of Monocyte Chemotactic Protein 1 by Chlamydia pneumoniae in Human Endothelial Cells. Infection and Immunity, 2000, 68, 4282-4288.	1.0	63
38	Inhibition of Chlamydia pneumoniaeReplication in Human Aortic Smooth Muscle Cells by Gamma Interferon-Induced Indoleamine 2,3-Dioxygenase Activity. Infection and Immunity, 2000, 68, 6478-6481.	1.0	60
39	Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine, 2013, 107, 1101-1111.	1.3	59
40	Clinical and economic burden of pneumonia among adults in Latin America. International Journal of Infectious Diseases, 2010, 14, e852-e856.	1.5	58
41	Improving Antimicrobial Use in the Hospital Setting by Providing Usage Feedback to Prescribing Physicians. Infection Control and Hospital Epidemiology, 2006, 27, 378-382.	1.0	54
42	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	1.4	54
43	Future Research Directions in Pneumonia. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 256-263.	2.5	54
44	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine, 2019, 37, 3352-3361.	1.7	54
45	Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clinical Therapeutics, 1999, 21, 103-117.	1.1	53
46	Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis, 2008, 199, 154-161.	0.4	52
47	Characteristics associated with clinician diagnosis of aspiration pneumonia: A descriptive study of afflicted patients and their outcomes. Journal of Hospital Medicine, 2015, 10, 90-96.	0.7	52
48	Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. Inflammation, 2014, 37, 1158-1166.	1.7	51
49	Switch therapy in community-acquried pneumonia. Diagnostic Microbiology and Infectious Disease, 1995, 22, 219-223.	0.8	50
50	Ventilator-associated pneumonia in critically ill stroke patients: Frequency, risk factors, and outcomes. Journal of Critical Care, 2011, 26, 273-279.	1.0	47
51	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest, 2020, 158, 1008-1016.	0.4	46
52	Influenza and Viral Pneumonia. Clinics in Chest Medicine, 2018, 39, 703-721.	0.8	45
53	Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. International Journal of Antimicrobial Agents, 2011, 38, 291-295.	1.1	44
54	The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine, 2014, 32, 2198-2203.	1.7	42

#	Article	IF	CITATIONS
55	Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2011, 140, 482-488.	0.4	41
56	Cardiac diseases complicating community-acquired pneumonia. Current Opinion in Infectious Diseases, 2014, 27, 295-301.	1.3	41
57	A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia. Respiratory Care, 2014, 59, 1078-1085.	0.8	41
58	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	1.4	39
59	Ruling Out Legionella in Community-acquired Pneumonia. American Journal of Medicine, 2014, 127, 1010.e19.	0.6	39
60	Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review. Respiratory Medicine, 2014, 108, 1569-1580.	1.3	38
61	Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene. Clinical Infectious Diseases, 2011, 53, 766-771.	2.9	37
62	Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Critical Care, 2014, 18, R118.	2.5	37
63	Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respiratory Medicine, 2011, 105, 1732-1738.	1.3	35
64	Effect of Macrolide Antibiotics on Human Endothelial Cells Activated byChlamydia pneumoniaeInfection and Tumor Necrosis Factor–α. Journal of Infectious Diseases, 2002, 185, 1631-1636.	1.9	34
65	Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. European Respiratory Journal, 2013, 42, 742-749.	3.1	34
66	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	2.9	33
67	Predicting Mortality in Patients with Ventilatorâ€Associated Pneumonia: The APACHE II Score versus the New IBMPâ€10 Score. Clinical Infectious Diseases, 2009, 49, 72-77.	2.9	32
68	Effects of Fluoroquinolones on the Migration of Human Phagocytes through Chlamydia pneumoniae -Infected and Tumor Necrosis Factor Alpha-Stimulated Endothelial Cells. Antimicrobial Agents and Chemotherapy, 2004, 48, 2538-2543.	1.4	31
69	Analysis of Pathogen and Host Factors Related to Clinical Outcomes in Patients with Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus. Journal of Clinical Microbiology, 2012, 50, 1640-1644.	1.8	31
70	Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. International Journal of Infectious Diseases, 2010, 14, e84-e85.	1.5	30
71	Global Changes in the Epidemiology of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 213-219.	0.8	30
72	Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Critical Care, 2011, 15, R38.	2.5	29

#	Article	IF	CITATIONS
73	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respiratory Medicine, 2015, 109, 743-750.	1.3	29
74	Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course. Chest, 2020, 157, 34-41.	0.4	29
75	Is Microthrombosis the Main Pathology in Coronavirus Disease 2019 Severity?—A Systematic Review of the Postmortem Pathologic Findings. , 2021, 3, e0427.		29
76	Increased Rate of Tuberculin Skin Test Conversion among Workers at a University Hospital. Infection Control and Hospital Epidemiology, 1992, 13, 579-581.	1.0	28
77	Switch Therapy in Adult Patients with Pneumonia. Clinical Pulmonary Medicine, 1995, 2, 327-333.	0.3	28
78	Performance of School Buildings in Turkey During the 1999 Düzce and the 2003 Bingöl Earthquakes. Earthquake Spectra, 2009, 25, 239-256.	1.6	28
79	Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respiratory Medicine, 2010, 104, 1736-1743.	1.3	28
80	Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes. Journal of Critical Care, 2016, 35, 29-32.	1.0	28
81	A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. Clinical Infectious Diseases, 2018, 67, 736-742.	2.9	28
82	Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. International Journal of Infectious Diseases, 2010, 14, e22-e27.	1.5	27
83	Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. International Journal of Infectious Diseases, 2013, 17, e293-e298.	1.5	27
84	Emergence of methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of late-onset nosocomial pneumonia in intensive care patients in the USA. International Journal of Infectious Diseases, 2013, 17, e398-e403.	1.5	27
85	Acute myocardial infarction <i>versus</i> other cardiovascular events in community-acquired pneumonia. ERJ Open Research, 2015, 1, 00020-2015.	1.1	26
86	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. Chest, 2020, 158, 1912-1918.	0.4	26
87	Traumatic Experiences and Mental Health Risk for Refugees. International Journal of Environmental Research and Public Health, 2020, 17, 1943.	1.2	26
88	Postevent Reconnaissance Image Documentation Using Automated Classification. Journal of Performance of Constructed Facilities, 2019, 33, .	1.0	25
89	Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes. Journal of the American Geriatrics Society, 2020, 68, 1007-1014.	1.3	25
90	Community-acquired pneumonia in chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 2020, 33, 173-181.	1.3	24

#	Article	IF	CITATIONS
91	Axial Failure of Reinforced Concrete Columns Damaged by Shear Reversals. Journal of Structural Engineering, 2013, 139, 1172-1180.	1.7	23
92	Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. European Respiratory Journal, 2014, 43, 178-184.	3.1	23
93	Role of Atypical Pathogens in the Etiology of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 819-828.	0.8	22
94	Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Medical Informatics and Decision Making, 2016, 16, 34.	1.5	22
95	Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia. Chest, 2022, 161, 927-936.	0.4	22
96	Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy, 2003, 51, 1025-1028.	1.3	21
97	Increased Rate of Tuberculin Skin Test Conversion Among Workers at a University Hospital. Infection Control and Hospital Epidemiology, 1992, 13, 579-581.	1.0	21
98	Switch Therapy with $\hat{l}^2$ -Lactam/ $\hat{l}^2$ -Lactamase Inhibitors in Patients with Community-Acquired Pneumonia. Annals of Pharmacotherapy, 1998, 32, S22-S26.	0.9	20
99	Methicillin-resistant Staphylococcus aureus resistance to non–β-lactam antimicrobials in the United States from 1996 to 2008. Diagnostic Microbiology and Infectious Disease, 2010, 67, 395-398.	0.8	20
100	Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. European Respiratory Journal, 2013, 41, 1135-1140.	3.1	20
101	The value of ready-to-use disinfectant wipes: Compliance, employee time, and costs. American Journal of Infection Control, 2014, 42, 329-330.	1.1	20
102	Worldwide Perspective of the Quality of Care Provided to Hospitalized Patients with Community-Acquired Pneumonia: Results from the CAPO International Cohort Study. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 543-552.	0.8	19
103	Socioeconomic Position and the Incidence, Severity, and Clinical Outcomes of Hospitalized Patients With Community-Acquired Pneumonia. Public Health Reports, 2020, 135, 364-371.	1.3	19
104	Improving Antimicrobial Use: Longitudinal Assessment of an Antimicrobial Team Including a Clinical Pharmacist. Journal of Managed Care Pharmacy, 2004, 10, 152-158.	2.2	18
105	Patients with Obesity Have Better Long-Term Outcomes after Hospitalization for COPD Exacerbation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 373-377.	0.7	18
106	Inhibition of oxidative burst and chemotaxis in human phagocytes by Legionella pneumophila zinc metalloprotease. Journal of Medical Microbiology, 2001, 50, 517-525.	0.7	18
107	23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms, 2022, 10, 560.	1.6	18
108	How to choose the duration of antibiotic therapy in patients with pneumonia. Current Opinion in Infectious Diseases, 2015, 28, 177-184.	1.3	17

#	Article	IF	CITATIONS
109	Googling your hand hygiene data: Using Google Forms, Google Sheets, and R to collect and automate analysis of hand hygiene compliance monitoring. American Journal of Infection Control, 2018, 46, 617-619.	1.1	17
110	Plasma cysteine/cystine and glutathione/glutathione disulfide redox potentials in HIV and COPD patients. Free Radical Biology and Medicine, 2019, 143, 55-61.	1.3	17
111	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2021, 18, 1087-1097.	1.5	17
112	Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection. BMC Infectious Diseases, 2006, 6, 152.	1.3	16
113	Real-time enrollment dashboard for multisite clinical trials. Contemporary Clinical Trials Communications, 2015, 1, 17-21.	0.5	16
114	Phenotypic Differences in Virulence and Immune Response in Closely Related Clinical Isolates of Influenza A 2009 H1N1 Pandemic Viruses in Mice. PLoS ONE, 2013, 8, e56602.	1.1	16
115	Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan. Journal of Infection, 2007, 55, 214-219.	1.7	15
116	Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Scientific Reports, 2021, 11, 15715.	1.6	15
117	Managing Antiinfective Therapy of Community-Acquired Pneumonia in the Hospital Setting: Focus on Switch Therapy. Pharmacotherapy, 2001, 21, 79S-82S.	1.2	14
118	Legionnaires Disease and the Updated IDSA Guidelines for Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2004, 39, 1734-1737.	2.9	14
119	Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulmonary Pharmacology and Therapeutics, 2017, 45, 191-201.	1.1	13
120	Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. ERJ Open Research, 2021, 7, 00736-2020.	1.1	13
121	Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study The University of Louisville Journal of Respiratory Infections, 2017, 1, 3-11.	0.2	13
122	Discovery and predictive modeling of urine microbiome, metabolite and cytokine biomarkers in hospitalized patients with community acquired pneumonia. Scientific Reports, 2020, 10, 13418.	1.6	12
123	Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky. American Journal of Infection Control, 2012, 40, 440-445.	1.1	11
124	Absence of Gender-Based Differences in Outcome of Patients with Hospital-Acquired Pneumonia. Journal of Women's Health, 2013, 22, 1069-1075.	1.5	11
125	Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study. Pneumonia (Nathan Qld ), 2016, 8, 8.	2.5	11
126	Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. Diagnostic Microbiology and Infectious Disease, 2017, 89, 294-299.	0.8	11

#	Article	IF	CITATIONS
127	Process control charts in infection prevention: Make it simple to make it happen. American Journal of Infection Control, 2017, 45, 216-221.	1.1	11
128	The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Infectious Diseases, 2018, 50, 13-20.	1.4	11
129	Methods for computational disease surveillance in infection prevention and control: Statistical process control versus Twitter's anomaly and breakout detection algorithms. American Journal of Infection Control, 2018, 46, 124-132.	1.1	11
130	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	1.3	11
131	Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Infectious Diseases, 2019, 69, S33-S39.	2.9	11
132	Burden of Adults Hospitalized With Group B Streptococcal Infection. Journal of Infectious Diseases, 2021, 224, 1170-1178.	1.9	11
133	A Case of Concurrent Lyme Meningitis with Ehrlichiosis. Scandinavian Journal of Infectious Diseases, 1996, 28, 527-528.	1.5	10
134	Antigens of persistentChlamydia pneumoniaewithin coronary atheroma from patients undergoing heart transplantation. Journal of Clinical Pathology, 2012, 65, 171-177.	1.0	10
135	What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia?. Infectious Disease Clinics of North America, 2013, 27, 205-210.	1.9	10
136	Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center. American Journal of Infection Control, 2017, 45, 673-676.	1.1	10
137	Predicting the need for ICU admission in community-acquired pneumonia. Respiratory Medicine, 2019, 155, 61-65.	1.3	10
138	Community-acquired pneumonia in adults. Primary Care - Clinics in Office Practice, 2003, 30, 155-171.	0.7	9
139	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. International Journal of Infectious Diseases, 2011, 15, e822-e827.	1.5	9
140	Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin. BMC Infectious Diseases, 2012, 12, 159.	1.3	9
141	The role of infection prevention conferences to build and maintain knowledge-sharing networks: A longitudinal evaluation. American Journal of Infection Control, 2014, 42, 209-211.	1.1	9
142	Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010–2013. Open Forum Infectious Diseases, 2020, 7, ofaa262.	0.4	9
143	A process for analysis of sentinel events due to health care–associated infection. American Journal of Infection Control, 2007, 35, 501-507.	1.1	8
144	Clinical Scoring Tools. Infectious Disease Clinics of North America, 2013, 27, 33-48.	1.9	8

#	Article	IF	CITATIONS
145	What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?. Current Opinion in Infectious Diseases, 2015, 28, 164-170.	1.3	8
146	Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study. Lung, 2016, 194, 155-162.	1.4	8
147	Advances in antibiotic use: Switch therapy. Current Therapeutic Research, 1994, 55, 30-34.	0.5	7
148	The Use of Heteroduplex Analysis of Polymerase Chain Reaction Products to Support the Possible Transmission ofLegionella pneumophilaFrom a Malfunctioning Automobile Air Conditioner. Infection Control and Hospital Epidemiology, 2002, 23, 145-147.	1.0	7
149	Septicemia in Patients With AIDS Admitted to a University Health System: A Case Series of Eighty-Three Patients. Journal of the American Board of Family Medicine, 2012, 25, 318-322.	0.8	7
150	Understanding why low-risk patients accept vaccines: a socio-behavioral approach. BMC Research Notes, 2015, 8, 813.	0.6	7
151	Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia. Respiratory Medicine, 2022, 191, 106714.	1.3	7
152	Processes of care for community-acquired pneumonia. Infectious Disease Clinics of North America, 2004, 18, 843-859.	1.9	6
153	Multicenter, Multinational Observational Studies: A New Approach to Studying Community-acquired Pneumonia. Respiratory Care Clinics of North America, 2005, 11, 35-44.	0.5	6
154	Controlling multiple-drug-resistant organisms at the hospital level. Expert Opinion on Pharmacotherapy, 2006, 7, 1449-1455.	0.9	6
155	Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. Annals of the American Thoracic Society, 2018, 15, 1247-1255.	1.5	6
156	Reduction in Tuberculin Skin-Test Conversion Rate after Improved Adherence to Tuberculosis Isolation. Infection Control and Hospital Epidemiology, 1997, 18, 575-576.	1.0	5
157	Simultaneous Shear and Axial Failures of Reinforced Concrete Columns. , 2009, , .		5
158	Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae. American Journal of Infection Control, 2015, 43, 380-382.	1.1	5
159	Automated Recovery of Structural Drawing Images Collected from Postdisaster Reconnaissance. Journal of Computing in Civil Engineering, 2019, 33, .	2.5	5
160	Lung Cytokines and Systemic Inflammation in Patients with COPD. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	5
161	A Randomised Comparative Trial of Aztreonam Plus Cefazolin versus Ceftazidime for the Treatment of Nosocomial Pneumonia. Drug Investigation, 1994, 7, 117-126.	0.6	4
162	Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?. European Respiratory Journal, 2013, 41, 5-6.	3.1	4

#	Article	IF	CITATIONS
163	Evaluation of the effectiveness of improved hydrogen peroxide in the operating room. American Journal of Infection Control, 2014, 42, 1004-1005.	1.1	4
164	Visual grids for managing data completeness in clinical research datasets. Journal of Biomedical Informatics, 2015, 54, 337-344.	2.5	4
165	Cumplimiento con las guÃas nacionales en pacientes hospitalizados con neumonÃa adquirida en la comunidad: resultados del Estudio Capo en Venezuela. Archivos De Bronconeumologia, 2015, 51, 163-168.	0.4	4
166	Comparing posteroanterior with lateral and anteroposterior chest radiography in the initial detection of parapneumonic effusions. American Journal of Emergency Medicine, 2016, 34, 2402-2407.	0.7	4
167	Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study. Open Forum Infectious Diseases, 2021, 8, ofab135.	0.4	4
168	One-Year Mortality in Patients with Community-Acquired Pneumonia. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	4
169	Guidelines for community-acquired pneumonia in the US and Canada: A practical approach to antibiotic selection. Comprehensive Therapy, 2002, 28, 201-207.	0.2	3
170	The Use of Large Databases to Study Pneumonia: What is Their Value?. Clinics in Chest Medicine, 2011, 32, 481-489.	0.8	3
171	Adherence With National Guidelines in Hospitalized Patients With Community-acquired Pneumonia: Results From the CAPO Study in Venezuela. Archivos De Bronconeumologia, 2015, 51, 163-168.	0.4	3
172	Effectiveness of oseltamivir treatment on clinical failure in hospitalized patients with lower respiratory tract infection. BMC Infectious Diseases, 2021, 21, 1106.	1.3	3
173	Clinical Research in Pneumonia: Role of Artificial Intelligence. The University of Louisville Journal of Respiratory Infections, 2019, 3, 1-4.	0.2	3
174	Treatment of hospital-acquired pneumonia – Authors' Reply. Lancet Infectious Diseases, The, 2011, 11, 731-732.	4.6	2
175	Pneumonia and Mortality Beyond Hospital Discharge in Elderly Patients: Response. Chest, 2011, 139, 474-475.	0.4	2
176	Knowledge sharing among healthcare infection preventionists: the impact of public health professionals in a rural state. BMC Research Notes, 2012, 5, 387.	0.6	2
177	An iterative workflow for creating biomedical visualizations using Inkscape and D3.js. BMC Bioinformatics, 2015, 16, .	1.2	2
178	Disinfectant sprays versus wipes: Applications in behavioral health. American Journal of Infection Control, 2016, 44, 1698-1699.	1.1	2
179	Adults Hospitalized with Pneumonia in the United States: Incidence, Epidemiology and Mortality. Open Forum Infectious Diseases, 2017, 4, S571-S571.	0.4	2
180	Database Enabled Rapid Seismic Vulnerability Assessment of Bridges. Transportation Research Record, 2021, 2675, 1106-1120.	1.0	2

#	Article	IF	CITATIONS
181	Distribution of PCV13 Pneumococcal Serotypes in Patients With Community-Acquired Pneumonia Presenting at 20 United States Hospitals. Open Forum Infectious Diseases, 2015, 2, .	0.4	2
182	Tuberculosis is always a possibility (even in the intensive care unit). Revista Brasileira De Terapia Intensiva, 2016, 28, 97-9.	0.1	2
183	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. PLoS ONE, 2021, 16, e0258482.	1.1	2
184	Level of Recall Bias Regarding Pneumococcal Vaccination History among Adults Hospitalized with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	2
185	Frequency of Testing for <i>Clostridioides difficile</i> in Adults Hospitalized with Diarrhea in Louisville, Kentucky. Infection Control and Hospital Epidemiology, 2020, 41, s444-s444.	1.0	2
186	Antibiotic therapy of hospitalized patients with community-acquired pneumonia: an international perspective from the CAPO Cohort Study. The Journal of the Kentucky Medical Association, 2006, 104, 513-7.	0.1	2
187	Mental and physical health profile of Syrian resettled refugees. Primary Health Care Research and Development, 2022, 23, e21.	0.5	2
188	Frequency of stool specimen collection and testing for Clostridioides difficile of hospitalized adults and long-term care facility residents with new-onset diarrhea in Louisville, Kentucky. International Journal of Infectious Diseases, 2022, 120, 196-200.	1.5	2
189	Community-Acquired Pneumonia Due to Chlamydia pneumoniae. , 2002, , 501-509.		1
190	ACI 318 Structural Concrete Building Code: The Need for Member Size Factor on the Shear Strength of Beams and One-Way Slabs. , 2005, , 1.		1
191	Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response. Chest, 2010, 138, 1279-1280.	0.4	1
192	A single genotype of Acinetobacter baumannii expresses multiple antibiotic susceptibility phenotypes. American Journal of Infection Control, 2014, 42, 556-558.	1.1	1
193	The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study. Pneumonia (Nathan Qld ), 2015, 6, 83-89.	2.5	1
194	Possible role of tetracyclines on decreasing the accelerated aging process of well-controlled HIV patients on antiretroviral therapy. HIV and AIDS Review, 2015, 14, 133-137.	0.1	1
195	Long-term Mortality in Hospitalized Patients With Community-Acquired Pneumonia. American Journal of the Medical Sciences, 2017, 353, 421.	0.4	1
196	How can we improve clinical research in pneumonia?. Current Opinion in Pulmonary Medicine, 2018, 24, 220-226.	1.2	1
197	2195. Incidence of Acute Myocardial Infarction in Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2019, 6, S747-S748.	0.4	1

198 Nontuberculous mycobacterial pulmonary infections. , 2014, , 128-137.

#	Article	IF	CITATIONS
199	Analysis of the local and systemic cytokine response profiles in patients with community-acquired pneumonia. Relationship with disease severity and outcomes The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	1
200	Using Steroids in Patients with Community-Acquired Pneumonia at the University of Louisville Hospital: Who, What, and When. The University of Louisville Journal of Respiratory Infections, 2017, 1,	0.2	1
201	Community-Acquired Pneumonia in the Elderly Reply. Southern Medical Journal, 1997, 90, 863-864.	0.3	0
202	Guidelines for Community-Acquired Pneumonia Within Disease Management Programs. Disease Management and Health Outcomes, 2003, 11, 33-43.	0.3	0
203	Atypical Coverage for Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1289-1290.	2.5	0
204	The Challenge of Predicting Influenza. Frontiers in Microbiology, 2011, 2, 45.	1.5	0
205	Risk factors for pulmonary tuberculosis in community-acquired pneumonia. European Respiratory Journal, 2014, 43, 1214-1214.	3.1	0
206	Addressing the challenges of refugee health: Experiences from the University of Louisville interprofessional refugee immunization clinic. Journal of Nursing Education and Practice, 2015, 5, .	0.1	0
207	Kawasaki-like disease (KLD) in an adult with congenital HIV infection. HIV and AIDS Review, 2016, 15, 47-50.	0.1	0
208	PREDICTING ADMISSION TO THE ICU IN COMMUNITY-ACQUIRED PNEUMONIA. Chest, 2018, 154, 145A.	0.4	0
209	Response. Chest, 2020, 158, 2703-2704.	0.4	0
210	Clinical Outcomes of Immunocompromised Adults Hospitalized with Pneumococcal Pneumonia: A Case-Control Study. Microorganisms, 2021, 9, 1746.	1.6	0
211	Seeking diagnostic and prognostic biomarkers for childhood bacterial pneumonia in sub-Saharan Africa: study protocol for an observational study. BMJ Open, 2021, 11, e046590.	0.8	0
212	TB Test Results May Be Skewed. Infection Control and Hospital Epidemiology, 1993, 14, 192-193.	1.0	0
213	Why a new journal?. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	0
214	Neutrophil function in elderly patients hospitalized with community-acquired pneumonia The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	0
215	The presence of COPD does not influence clinical outcomes in hospitalized patients with community-acquired pneumonia The University of Louisville Journal of Respiratory Infections, 2017, 1,	0.2	0
216	Pneumonia research and the Omics revolution: it is time for pneumOmics The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	0

#	Article	IF	CITATIONS
217	Clinical & Translational Research in Pneumonia: Defining a Research Agenda for Today and Tomorrow. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	О
218	Health Profiles of Newly Arriving Refugees In Kentucky, 2016: Data from the University of Louisville Global Health Program. Journal of Refugee & Global Health, 2017, 1, .	0.2	0
219	Pneumonia Pathogenesis and the Lung Microbiome: Back to the Drawing Board. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	О
220	Clinical Research: From Idea to Publication. The University of Louisville Journal of Respiratory Infections, 2018, 2, .	0.2	0
221	Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP). , 2018, , .		Ο
222	Current and Future Antivirals Medications to Treat Influenza: Mechanisms of Action. The University of Louisville Journal of Respiratory Infections, 2019, 3, .	0.2	0
223	Combination antibiotic therapy and synergy in HAP and VAP. , 0, , 302-311.		Ο
224	Frequency of Testing for <i>Clostridioides difficile</i> in Long-Term Care Facilities in Louisville, Kentucky. Infection Control and Hospital Epidemiology, 2020, 41, s445-s445.	1.0	0
225	756. <i>Clostridioides difficile</i> Burden of Disease: A Prospective Population-Based Surveillance Study of Hospitalized Adults in Louisville, Kentucky. Open Forum Infectious Diseases, 2021, 8, S475-S476.	0.4	0